Using NGS for microRNA and gene expression analysis with integrated bioinformatics for pathway discovery and biomarker verification
MicroRNAs (miRNAs) are small RNAs with an average size of 22 nucleotides that regulate gene expression through various mechanisms. During the last decade, researchers have identified over 2600 mature microRNAs in humans. Today, researchers are focusing on identifying key miRNAs that can serve as biomarkers for early detection of diseases, stratification of disease states and selection of potential therapies.
This webinar will focus on miRNA profiling from biofluids, such as serum and plasma, while looking at solutions across fresh and FFPE samples. Our webinar will highlight best practices in miRNA isolation, NGS library construction, data analysis and downstream biological verification.
This webinar will focus on miRNA profiling from biofluids, such as serum and plasma, while looking at solutions across fresh and FFPE samples. Our webinar will highlight best practices in miRNA isolation, NGS library construction, data analysis and downstream biological verification.
About the speaker
Samuel Rulli Jr., Associate Director, Global Product Management, Genomics
QIAGEN
Dr. Samuel Rulli received his Ph.D. in Molecular and Cellular Biology from Tulane University in 2002,studying the gastric proton pump. After his postdoctoral training at Johns Hopkins University and the National Cancer Institute, he joined QIAGEN in 2009. As the Associate Director of Global Product Management for NGS technologies, Samuel has been instrumental in developing gene expression analysis solutions for qPCR and NGS.
Categories
Next Generation Sequencing
Biomedical Research
Infectious Disease
Gene Expression/Regulation